186 related articles for article (PubMed ID: 17317812)
1. Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?
Arteaga CL
Clin Cancer Res; 2007 Feb; 13(4):1071-3. PubMed ID: 17317812
[No Abstract] [Full Text] [Related]
2. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
3. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.
Harris LN; You F; Schnitt SJ; Witkiewicz A; Lu X; Sgroi D; Ryan PD; Come SE; Burstein HJ; Lesnikoski BA; Kamma M; Friedman PN; Gelman R; Iglehart JD; Winer EP
Clin Cancer Res; 2007 Feb; 13(4):1198-207. PubMed ID: 17317830
[TBL] [Abstract][Full Text] [Related]
4. Is trastuzumab active following conventional adjuvant chemotherapy in HER2-positive early breast cancer?
Seidman AD
Nat Clin Pract Oncol; 2006 Apr; 3(4):178-9. PubMed ID: 16596138
[No Abstract] [Full Text] [Related]
5. The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
Pegram MD; Konecny G; Slamon DJ
Cancer Treat Res; 2000; 103():57-75. PubMed ID: 10948442
[No Abstract] [Full Text] [Related]
6. Her2-positive breast cancer: herceptin and beyond.
Dean-Colomb W; Esteva FJ
Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
[TBL] [Abstract][Full Text] [Related]
7. HER2/neu in the management of invasive breast cancer.
Meric F; Hung MC; Hortobagyi GN; Hunt KK
J Am Coll Surg; 2002 Apr; 194(4):488-501. PubMed ID: 11949754
[No Abstract] [Full Text] [Related]
8. Resistance to trastuzumab: a necessary evil or a temporary challenge?
Cardoso F; Piccart MJ; Durbecq V; Di Leo A
Clin Breast Cancer; 2002 Oct; 3(4):247-57; discussion 258-9. PubMed ID: 12425752
[TBL] [Abstract][Full Text] [Related]
9. ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines.
Ginestier C; Adélaïde J; Gonçalvès A; Repellini L; Sircoulomb F; Letessier A; Finetti P; Geneix J; Charafe-Jauffret E; Bertucci F; Jacquemier J; Viens P; Birnbaum D
Oncogene; 2007 Nov; 26(50):7163-9. PubMed ID: 17525746
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab (herceptin) for early-stage breast cancer.
Ismael G; Rosa DD; de Azambuja E; Braga S; Piccart-Gebhart M
Hematol Oncol Clin North Am; 2007 Apr; 21(2):239-56. PubMed ID: 17512447
[TBL] [Abstract][Full Text] [Related]
11. Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland.
Ann Oncol; 2001; 12 Suppl 1():1-107. PubMed ID: 11816498
[No Abstract] [Full Text] [Related]
12. The distinctive nature of HER2-positive breast cancers.
Burstein HJ
N Engl J Med; 2005 Oct; 353(16):1652-4. PubMed ID: 16236735
[No Abstract] [Full Text] [Related]
13. Focus on ERBB2.
Benusiglio PR
Pharmacogenomics; 2008 Jul; 9(7):825-8. PubMed ID: 18597646
[No Abstract] [Full Text] [Related]
14. Meningeal carcinomatosis in HER2-overexpressing breast cancers.
Bidard FC; Guilhaume MN; Gauthier H; Cottu PH; Diéras V; Pierga JY
J Neurooncol; 2009 Jun; 93(2):287-8. PubMed ID: 19139826
[No Abstract] [Full Text] [Related]
15. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
Valabrega G; Montemurro F; Aglietta M
Ann Oncol; 2007 Jun; 18(6):977-84. PubMed ID: 17229773
[TBL] [Abstract][Full Text] [Related]
16. Her2 and trastuzumab in breast cancer.
Horton J
Cancer Control; 2001; 8(1):103-10. PubMed ID: 11176040
[No Abstract] [Full Text] [Related]
17. [Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].
Dieras V; Vincent-Salomon A; Degeorges A; Beuzeboc P; Mignot L; de Cremoux P
Bull Cancer; 2007 Mar; 94(3):259-66. PubMed ID: 17371768
[TBL] [Abstract][Full Text] [Related]
18. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
19. Spotlight on trastuzumab as adjuvant treatment in human epidermal growth factor receptor 2 (HER2)-positive early breast cancer.
Garnock-Jones KP; Keating GM; Scott LJ
BioDrugs; 2010 Jun; 24(3):207-9. PubMed ID: 20462285
[No Abstract] [Full Text] [Related]
20. Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.
Vazquez-Martin A; Cufí S; Oliveras-Ferraros C; Martin-Castillo B; Del Barco S; López-Bonet E; Menendez JA
Genes Chromosomes Cancer; 2011 Apr; 50(4):284-90. PubMed ID: 21319263
[No Abstract] [Full Text] [Related]
[Next] [New Search]
